Fusilev for injection contains levoleucovorin calcium, which is one of several active, chemically reduced derivatives of folic acid. It is useful as antidote to the inhibition of dihydrofolate reductase by methotrexate.
Limitations of Use
- FusilevÖ is a folate analog.
- Fusilev rescue is indicated after high-dose methotrexate therapy in osteosarcoma.
- Fusilev is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.
- Fusilev is not approved for pernicious anemia and megaloblastic anemias secondary to the lack of vitamin B12. Improper use may cause a hematologic remission while neurologic manifestations continue to progress.
Clinical Trials Related to Fusilev (Levoleucovorin)
Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer [Recruiting]
The study is an open label, randomized phase 3 study of MM-398 with or without
5-Fluorouracil (5-FU) and Leucovorin (also known as folinic acid), versus 5-FU and
leucovorin in metastatic pancreatic cancer patients who have progressed on prior gemcitabine
A Folinic Acid Intervention for Autism Spectrum Disorders [Recruiting]
Researchers at Arkansas Children's Hospital Research Institute are conducting a study
looking at the effects of Folinic Acid on language in Autism Spectrum Disorder and language
impairment. The study has 3 phases. Phase 1 confirms that your child has language impairment
(there is no compensation for this visit). If language impairment is verified in the phase 1
screening, then your child will be eligible for phase 2. Phase 2 consists of receiving 12
weeks of folinic acid or an inactive placebo, in addition to several evaluations of your
child's abilities and blood tests. Children in the placebo group during phase 2 will be
offered to receive 12 weeks of the folinic acid intervention after they have completed Phase
Study of Combination Treatment With IMO-2125 and Ribavirin in Na├»ve Hepatitis C-infected, Genotype 1 Patients [Recruiting]
Phase 1, randomized, double-blind, placebo-controlled, dose-escalation study with 3 dose
levels of IMO-2125 in combination with standard weight based ribavirin (investigational
treatment arm) or placebo in combination with ribavirin (RBV). Each cohort of 15 patients
will be randomized 4: 1 to receive the investigational treatment arm (12 patients) or placebo
and RBV arm (3 patients).
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) [Recruiting]
The goal of this clinical research study is to find the highest tolerable doses of the
combinations of lenalidomide and other drugs that can be given to patients with advanced
cancer. The safety of the drug combinations will also be studied.
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab [Recruiting]
The goal of this clinical research study is to find the best combination of oxaliplatin,
bevacizumab, 5-fluorouracil, leucovorin, and cetuximab that can be given to patients with
advanced cancer that has spread to the liver. Different combinations of these drugs will be
used, and the safety of all drug combinations will also be studied.
Reports of Suspected Fusilev (Levoleucovorin) Side Effects
Infusion Related Reaction (2),
Infusion Site Reaction (1),
Hypoglycaemic Coma (1),
White Blood Cell Count Decreased (1), more >>
Page last updated: 2008-09-29